TNFSF13B Recombinant Antibody: Essential Insights for Research Use

The TNFSF13B recombinant antibody from Alpha Lifetech Incorporation is a cutting-edge tool designed for research in immunology and cell biology. This high-quality antibody specifically targets the TNFSF13B Protein, also known as BAFF (B-cell activating factor), which plays a vital role in B cell maturation and survival. By facilitating various cellular interactions, it is crucial for understanding autoimmune diseases and lymphoproliferative disorders, Developed using advanced recombinant technology, this antibody offers enhanced specificity and sensitivity, making it an essential addition to any laboratory investigating B cell-related mechanisms. Its versatility allows for utilization in various applications, including Western blotting, immunoprecipitation, and ELISA, Researchers can trust Alpha Lifetech's commitment to quality and excellence, ensuring reliable and reproducible results. Unlock new insights into your research with the TNFSF13B recombinant antibody, designed to support your scientific endeavors effectively. Experience the difference in your experiments with this innovative solution from a leader in the field

Hot Selling Product

ADT1646-Tibulizumab Biosimilar-(IL17A/TNFSF13B/CD257)-Research Biosimilar Antibody

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64512-Recombinant Human CD96 Protein, Fc Tag

Why Opt For TNFSF13B recombinant antibody Custom Solutions, Your End-to-End Solution

In the rapidly evolving field of biochemistry and pharmaceuticals, the demand for high-quality therapeutic solutions is paramount. At Alpha Lifetech Inc., we understand the unique challenges researchers and manufacturers face in obtaining reliable reagents. This is where our TNFSF13B recombinant antibody custom solutions come in, providing an end-to-end answer that adheres to the highest standards of quality and specificity. Our experienced team of scientists, having pioneered in membrane protein production and monoclonal development, is dedicated to delivering tailored products to meet your specific research needs. Choosing TNFSF13B recombinant antibodies from Alpha Lifetech not only ensures superior performance but also guarantees a seamless procurement experience. Our extensive catalog of nearly 10,000 high-quality spot membrane protein reagents and cytokines allows for rapid access to critical components necessary for successful research outcomes. Our custom solutions are designed to help you navigate complex pathways, enhance your research timelines, and ultimately accelerate your scientific discoveries. With our commitment to innovation and excellence, we empower researchers around the globe to take their projects to the next level. Join us in advancing biotherapeutics by choosing Alpha Lifetech Inc. for your TNFSF13B recombinant antibody custom solutions. Experience the difference that our expertise and dedication can make in your research projects, and allow us to support you in your journey towards groundbreaking discoveries. Your success is our mission, and together, we can drive forward the frontiers of science.

Why Opt For TNFSF13B Recombinant Antibody Custom Solutions, Your End-to-End Solution

Feature	Description	Benefits
Customizability	Tailor-made antibodies specific to your research needs.	Enhanced specificity and sensitivity for your applications.
Quality Assurance	Rigorous quality control measures in place.	Reliable performance and reproducibility.
Technical Support	Expert guidance throughout the selection and usage process.	Maximized efficiency in research projects.
Flexible Delivery Options	Various delivery formats and timelines available.	Aids in planning experiments according to your schedule.
Cost-Effective	Competitive pricing for high-quality products.	Budget-friendly solutions for research institutions.

Analysis of TNFSF13B Antibody Research Trends Over Time

The chart illustrates the rising trend in the number of publications related to TNFSF13B recombinant antibodies from 2018 to 2023. Over this period, research on TNFSF13B has gained significant traction, with publications increasing from 50 in 2018 to an estimated 140 in 2023. This notable growth in research output signals an increasing interest in the potential applications of TNFSF13B antibodies in diverse fields, including immunology and therapeutic interventions. The upward trajectory is indicative of the expanding research landscape and the potential implications for future studies and clinical practices. Researchers and institutions are likely to benefit from comprehensive solutions that support the development and application of TNFSF13B antibodies, thereby enhancing the overall impact of their work in the scientific community.